SREBF1 and metabolic dysfunction-associated steatotic liver disease: A significant increase in hepatic levels of SREBP‐1c and its target lipid synthesis enzymes, FASN and ACC, is observed in NAFLD patients as well as in HFD‐fed rodents, which is followed by a large amount of TG deposition.26, 27